Palantir Board Member Cofounded Elizabeth Holmes’ Partner’s Blood-Testing Startup

A connection has emerged between a member of the Palantir board and a blood-testing startup founded by Billy Evans, who is identified as the partner of Elizabeth Holmes. According to reporting from Forbes, the Palantir board member served as a cofounder of this specific venture. The startup is currently facing internal instability, as Forbes further reports that the company has lost its Chief Technology Officer. This development adds a layer of corporate complexity to the venture, linking a high-profile board member of a major data analytics firm to a company associated with the partner of the disgraced Theranos founder. Coverage from Fortune and NewsNation emphasizes the precarious state of the business, with Fortune describing the venture as a 'Theranos 2.0.' Fortune reports that while the startup possesses patents and has secured investors, it currently has no actual product to offer.

Meanwhile, NewsNation reports that the AI startup led by Billy Evans has caused worry for a whistleblower previously associated with Theranos. These reports collectively highlight a pattern of concern regarding the legitimacy and operational health of the organization, specifically noting the contradiction between its financial backing and its lack of a tangible product. The context of this trend is rooted in the legacy of Theranos and Elizabeth Holmes, as the current startup's association with Holmes' partner has prompted comparisons to the previous blood-testing scandal. The involvement of a Palantir board member provides a direct link to established industry leadership, while the reports of a missing CTO and a lack of product mirror the red flags often discussed in the wake of the Theranos collapse. The mention of a whistleblower's concerns in NewsNation suggests that those familiar with the previous failure are monitoring Evans' current activities with significant apprehension.

Future developments to monitor include the identity of the Palantir board member involved and any official responses from Palantir or Billy Evans regarding the claims. Based on the reporting from Fortune and Forbes, the status of the company's leadership following the loss of its CTO remains a key point of interest. Additionally, the nature of the patents mentioned by Fortune and the specific concerns raised by the Theranos whistleblower reported by NewsNation are critical details that may emerge as the situation evolves. The gap between the startup's investment levels and its lack of a product continues to be a primary focal point of the current coverage.